Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data BioSpaceThe FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.RegulatoryMetabolic & GLP-1Read full story pharminent April 15, 2026 BioSpace The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In SilicoNext: Amazon launches its AI drug discovery platform Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026